AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The controlled-release formulation of paroxetine was approved by the Food and Drug Administration for treating premenstrual dysphoric disorder, based on data in more than 1,000 women who met the DSM-IV criteria for the disorder.
This is the third drug (and the third selective serotonin reuptake inhibitor) approved for PMDD. Fluoxetine, marketed as Sarafem for this indication, and sertraline (Zoloft) have been approved previously. Both can be taken daffy throughout the cycle or during the luteal phase only.
The dosing schedule approved for controlled-release paroxerine, marketed as Paxil CE by GlaxoSmithKline, is a daily dose taken continuously throughout the cycle, but the company said that the intermittent dosing for PMDD is under review at the FDA. The recommended initial dose is 12.5 mg per day
In the trials, which together included 1,030 women with PMDD, those randomized to receive 12.5 mg or 25 mg per day for three menstrual cycles had statistically and clinically significant responses to treatment, compared with those who took a placebo.
One of the lead investigators, Dr. Kimberley Yonkers of the department of psychiatry at Yale University, New Haven, said that the treatment had a "robust" effect and that the lower dose was almost as ...